Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Gene Expression Classifier Testing On Adjuvant Treatment Following Radical Prostatectomy: The G-minor Prospective Randomized Cluster-crossover Trial.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Impact Of Gene Expression Classifier Testing On Adjuvant Treatment Following Radical Prostatectomy: The G-minor Prospective Randomized Cluster-crossover Trial.

Related Experiment Video

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.

Todd M Morgan1, Stephanie Daignault-Newton1, Daniel E Spratt2

  • 1University of Michigan, Ann Arbor, MI, USA.

European Urology
|October 8, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Adjuvant therapyBiomarkersProstate cancerProstate radiotherapy

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Related Experiment Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Genomic classifier (GC) testing influenced adjuvant treatment decisions in prostate cancer patients, particularly when using risk categories. However, current data do not definitively support GC testing for adjuvant treatment benefits.

Area of Science:

  • Urology
  • Genomics
  • Oncology

Background:

  • Decipher is a validated genomic classifier (GC) for predicting metastasis after radical prostatectomy (RP).
  • A prospective trial assessed the impact of GC-guided care on adjuvant treatment decisions post-RP.

Purpose of the Study:

  • To evaluate the impact of Decipher genomic classifier (GC) testing on adjuvant treatment decisions after radical prostatectomy (RP).
  • To assess the influence of GC results on treatment choices in patients with high-risk prostate cancer.

Main Methods:

  • A prospective randomized controlled cluster-crossover trial design was employed.
  • Centers alternated between GC-informed care and usual care (UC) over 3-month periods.
  • Patients with pT3-4 disease or positive margins and PSA <0.1 ng/mL were included.
Prostatectomy gene expression testing

Main Results:

  • No significant difference in adjuvant treatment rates between GC-informed care and UC (9.7% vs. 8.7%).
  • Higher GC scores showed a non-significant trend towards increased adjuvant treatment (OR=1.35).
  • High GC risk groups significantly increased odds of adjuvant treatment compared to low GC risk (OR=6.9, p=0.005), adjusted for CAPRA-S.

Conclusions:

  • Genomic classifier (GC) testing influences adjuvant therapy decisions when interpreted using risk categories.
  • The study did not find definitive evidence supporting GC testing for adjuvant treatment benefits in prostate cancer.
  • No differences in patient-reported urinary or sexual function were observed between arms.